BRPI0811333B8 - proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica - Google Patents

proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica

Info

Publication number
BRPI0811333B8
BRPI0811333B8 BRPI0811333A BRPI0811333A BRPI0811333B8 BR PI0811333 B8 BRPI0811333 B8 BR PI0811333B8 BR PI0811333 A BRPI0811333 A BR PI0811333A BR PI0811333 A BRPI0811333 A BR PI0811333A BR PI0811333 B8 BRPI0811333 B8 BR PI0811333B8
Authority
BR
Brazil
Prior art keywords
fusion protein
vector
dna sequence
immunoglobulin
pharmaceutical composition
Prior art date
Application number
BRPI0811333A
Other languages
English (en)
Inventor
Fang Jianmin
Liu Zheng
Original Assignee
Yantai Rongchang Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Rongchang Biotechnologies Co Ltd filed Critical Yantai Rongchang Biotechnologies Co Ltd
Publication of BRPI0811333A2 publication Critical patent/BRPI0811333A2/pt
Publication of BRPI0811333B1 publication Critical patent/BRPI0811333B1/pt
Publication of BRPI0811333B8 publication Critical patent/BRPI0811333B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

proteína de fusão compreendida de taci truncado e de imunoglobulina pc, seqüência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica. trata-se de uma proteína de fusão otimizada que compreende a região extracelular truncada de n-terminal de taci (ativador de transmembrana e interator de caml) e fc, uma seqüência de dna que codifica a proteína de fusão, um vetor e a célula hospedeira que compreende a proteína de fusão. também são apresentados um método e uso na preparação da proteína de fusão para o tratamento de doenças.
BRPI0811333A 2007-06-15 2008-06-16 proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica BRPI0811333B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH200710111162.2 2007-06-15
CN2007101111622A CN101323643B (zh) 2007-06-15 2007-06-15 优化的TACI-Fc融合蛋白
PCT/CN2008/001162 WO2008154814A1 (en) 2007-06-15 2008-06-16 OPTIMIZED TACI-Fc FUSION PROTEINS

Publications (3)

Publication Number Publication Date
BRPI0811333A2 BRPI0811333A2 (pt) 2015-06-16
BRPI0811333B1 BRPI0811333B1 (pt) 2020-09-15
BRPI0811333B8 true BRPI0811333B8 (pt) 2021-05-25

Family

ID=40155884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811333A BRPI0811333B8 (pt) 2007-06-15 2008-06-16 proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica

Country Status (8)

Country Link
US (1) US8193316B2 (pt)
EP (1) EP2161287B1 (pt)
JP (1) JP5372917B2 (pt)
KR (1) KR101204229B1 (pt)
CN (1) CN101323643B (pt)
BR (1) BRPI0811333B8 (pt)
RU (1) RU2433141C2 (pt)
WO (1) WO2008154814A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
JP2014504869A (ja) * 2011-01-06 2014-02-27 コンプリクス エン ヴェー サイトカインもしくは成長因子および／またはサイトカイン受容体もしくは成長因子受容体に特異的に結合するアルファボディー
CN102085368B (zh) * 2011-01-19 2013-06-12 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
CN102085367B (zh) * 2011-01-19 2012-08-22 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
CN103833856B (zh) * 2012-11-22 2017-05-03 上海康岱生物医药技术股份有限公司 抑制taci‑baff复合物形成的融合蛋白及其制法和用途
CN103936833B (zh) * 2014-04-18 2016-02-10 天津大学 BLyS拮抗肽、含TC-Fc融合蛋白基因的质粒及TC-Fc融合蛋白
CN110945030A (zh) * 2017-06-20 2020-03-31 丹娜法伯癌症研究院 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
CN110522908A (zh) * 2018-05-25 2019-12-03 荣昌生物制药（烟台）有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
JP7326500B2 (ja) * 2019-12-10 2023-08-15 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質医薬品製剤
KR20220034742A (ko) 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
WO2022206872A1 (zh) * 2021-03-31 2022-10-06 江苏恒瑞医药股份有限公司 截短的taci多肽及其融合蛋白和用途
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
KR20240005815A (ko) 2021-08-10 2024-01-12 레메젠 코, 리미티드 TACI-Fc 융합 단백질을 이용한 IgA 신장병증 치료 방법
EP4296287A1 (en) 2021-09-30 2023-12-27 RemeGen Co., Ltd. Method for treating sjogren's syndrome using taci-fc fusion protein
CN117916273A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 抗il23抗体融合蛋白及用途
TW202334225A (zh) * 2021-11-11 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｃｏｓｌ抗體融合蛋白及用途
AU2023283931A1 (en) * 2022-06-08 2024-05-16 Remegen Co., Ltd. Method for treating myasthenia gravis with taci-fc fusion protein
WO2024046301A1 (zh) * 2022-08-29 2024-03-07 江苏恒瑞医药股份有限公司 包含taci多肽的融合蛋白及其用途
WO2024067756A1 (zh) * 2022-09-30 2024-04-04 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗膜性肾病的方法
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253920B2 (en) * 2000-04-27 2006-03-16 Apoxis Sa Use of taci as an anti-tumor agent
PT1436003E (pt) * 2001-05-24 2010-03-12 Zymogenetics Inc Proteínas de fusão imunoglobulina taci
CA2585927A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
EP1922079A2 (en) * 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN100471872C (zh) * 2005-11-04 2009-03-25 余波 包含vegf受体片段的优化融合蛋白质及其医疗应用

Also Published As

Publication number Publication date
US8193316B2 (en) 2012-06-05
BRPI0811333B1 (pt) 2020-09-15
KR101204229B1 (ko) 2012-11-26
US20100136008A1 (en) 2010-06-03
EP2161287B1 (en) 2015-03-04
WO2008154814A1 (en) 2008-12-24
EP2161287A1 (en) 2010-03-10
BRPI0811333A2 (pt) 2015-06-16
EP2161287A4 (en) 2010-08-11
CN101323643A (zh) 2008-12-17
KR20100009600A (ko) 2010-01-27
JP2010529967A (ja) 2010-09-02
CN101323643B (zh) 2010-12-01
JP5372917B2 (ja) 2013-12-18
RU2433141C2 (ru) 2011-11-10
RU2009148020A (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
BRPI0811333B8 (pt) proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, microrganismo transgênico, uso da proteína de fusão, e composição farmacêutica
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
UY31123A1 (es) Proteinas de fusion natriureticas
NO20092414L (no) Modifiserte loselige FGF-reseptor FC-fusjoner med forbedret biologisk aktivitet
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
CL2011002768A1 (es) Polipéptido mutante fgf21; ácido nucleico que lo codifica; vector; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar un trastorno metabólico.
AR062069A1 (es) Replegado de proteinas recombinantes
EA200970231A1 (ru) СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
CL2013003182A1 (es) Molécula quimérica que comprende un polipéptido de fusión que comprende el anticuerpo anti-mesotelina ss1p, una secuencia enlazadora, un sitio de corte para furina, una secuencia enlazadora y el dominio funcional iii de una endotoxina a de pseudomonas modificada (pe); composicion farmacéutica; ácido nucleico; vector; célula huésped, usos
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
HK1135112A1 (en) Exendin fusion proteins
BRPI0911385B8 (pt) polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CL2010000720A1 (es) Método para la evaluar la respuesta a la inhibición de her en una muestra de paciente, que comprende detectar la proteina marcadora egf (div.sol.no. 1240-06).
BRPI0618449A2 (pt) métodos para produção de isoformas de receptor e ligante
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
WO2008025516A3 (en) Tnf superfamily fusion proteins
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
UY30925A1 (es) Proteinas de fusion de inmunoglobulina y metodos de elaboracion
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF